Paris, France

Rémi Delansorne

USPTO Granted Patents = 5 


 

Average Co-Inventor Count = 2.5

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2008-2019

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Rémi Delansorne: Innovating Cancer Treatment in Paris

Introduction

Rémi Delansorne is a notable inventor based in Paris, France, recognized for his significant contributions to cancer treatment through innovative pharmaceutical developments. With a total of four patents to his name, his work focuses on advancing therapies that enhance treatment efficacy for hematological malignancies.

Latest Patents

Among his latest patents, one key invention addresses the combinations of inecalcitol with an anti-CD38 agent, emphasizing its use in treating cancer. This invention explores the synergistic potential of inecalcitol with agents such as daratumumab, MOR 202, or isatuximab, aimed at increasing or inducing the expression of CD-38 in targeting hematological malignancies. Another noteworthy patent involves cysteine protease inhibitors, detailing new compounds and their therapeutic applications, which hold promise for various medical treatments.

Career Highlights

Rémi Delansorne’s career has been marked by groundbreaking research and development in the pharmaceutical field. Currently affiliated with Hybrigenics S.A., he has played a crucial role in leading innovative projects that push the boundaries of current cancer treatments. His dedication to research and the application of novel compounds has solidified his reputation as a forward-thinking inventor.

Collaborations

Collaboration is key in scientific research, and Delansorne has worked alongside esteemed colleagues such as Philippe Guedat and Guillaume Boissy. Together, they contribute to advancing knowledge in therapeutic developments, fostering an environment of innovation and teamwork within the industry.

Conclusion

In summary, Rémi Delansorne exemplifies the spirit of innovation in the realm of cancer treatment. His four patents reflect a commitment to solving complex health challenges, and his collaborations with skilled professionals enhance his potential to effect real change in the medical field. As he continues his work at Hybrigenics S.A., the future looks promising for advancements arising from his research initiatives.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…